Screener
BioCryst Pharmaceuticals BCRX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's deferred revenue?
- BioCryst Pharmaceuticals (BCRX) reported deferred revenue of $12.32M in Q2 2026.
- What is the long-term trend for BioCryst Pharmaceuticals's deferred revenue?
- Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $150K to $0.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about BioCryst Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude